Clinical trials: Neoadjuvant Therapies
Triple Negative Breast Cancer
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in…
- Trial name
- NCT02032277
- Testing
- Cyclophosphamide, Doxorubicin, Paclitaxel
- Where
- 158 sites in United States, Australia and 13 more
- Volunteers
- 634 people
- Sponsor
- AbbVie
Breast Cancer
Axillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant Chemotherapy
For patients with early breast cancer with negative axillary lymph nodes, sentinel lymph node biopsy (SLNB) can largely avoid complications such as upper limb lymphoedema caused by axillary lymph node dissection (ALND).
- Trial name
- NCT05241119
- Testing
- SLNB, pALND, ALND
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Shengjing Hospital
Neoplasms, Breast
Treatment With Pazopanib for Neoadjuvant Breast Cancer
The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a…
- Trial name
- NCT00849472
- Testing
- doxorubicin + cyclophosphamide, paclitaxel + pazopanib, surgery
- Where
- 143 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- GlaxoSmithKline
Triple Negative Breast Cancer
Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC
To evaluate the efficacy and safety of P nab-paclitaxel combined with carboplatin versus paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide in the neoadjuvant treatment of triple negative breast…
- Trial name
- NCT04067102
- Testing
- Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide, paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
- Where
- China
- Sponsor
- Hebei Medical University Fourth Hospital
Non Small Cell Lung Cancer
Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study
This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant Durvalumab/Anlotinib/Chemotherapy followed by surgery in resectable stage III non-small cell lung cancer.
- Trial name
- NCT04762030
- Testing
- Durvalumab Anlotinib Carboplatin Nab-paclitaxel
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Breast Cancer
Melatonin in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Melatonin is an attractive candidate with anticancer activities previously reported in various preclinical and clinical studies.
- Trial name
- NCT07067307
- Testing
- melatonin
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Mansoura University
Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma
Neoadjuvant Immunochemotherapy for LAOSCC
To evaluate the prognostic efficacy of neoadjuvant immunochemotherapy with tislelizumab, albumin paclitaxel and cisplatin followed by radical surgery and adjuvant therapy compared with standard therapy for patients with locally…
- Trial name
- NCT06258811
- Testing
- albumin paclitaxel, cispatin, tislelizumab
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Lai-ping Zhong
Resectable Pancreatic Cancer
Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients
This is a phase II multi-center study of nab-paclitaxel, gemcitabine and cisplatin (NGC triple regimen) as preoperative therapy in potentially resectable pancreatic cancer patients.
- Trial name
- NCT03392571
- Testing
- NGC-Triple regimen
- Sponsor
- Pancreatic Cancer Research Team
Pancreatic Cancer Resectable
Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer
Pancreatic cancer is one of the most treatment resistant malignancies, often diagnosed at a late stage and associated with poor survival. The 5-year overall survival rate remains around 10%.
- Trial name
- LEFT-PANC (NCT07155629)
- Testing
- mFOLFIRINOX neoadjuvant chemotherapy / Nab-paclitaxel and gemcitabine
- Where
- 2 sites in Finland
- Volunteers
- 381 people
- Sponsor
- Helsinki University Central Hospital
Rectal Cancer
No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer
This study is designed to explore the hypothesis that in patients with a Locally advanced rectal cancer (LARC) treated with a Total neoadjuvant therapy (TNT) strategy based on short course radiotherapy (5x5Gy) followed by…
- Trial name
- NOAHS-ARC (NCT04864067)
- Testing
- Oxaliplatin, 5-Fluoracil, Leucovorin
- Where
- 3 sites in Chile
- Volunteers
- 39 people
- Sponsor
- Servicio de Salud Metropolitano Sur Oriente
Breast Cancer
Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients
This is a multicenter, open-label, phase II trial to assess the efficacy of the GAT neoadjuvant regimen in patients with stage III breast cancer.
- Trial name
- NCT00128856
- Testing
- Gemcitabine, Adriamycine, Paclitaxel
- Where
- 10 sites in Spain
- Volunteers
- 46 people
- Sponsor
- Spanish Breast Cancer Research Group
Prostate Cancer, Prostate
Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.
The goal of this study is to evaluate the efficacy and safety of darolutamide combined with docetaxel and ADT compared to docetaxel combined with ADT in treating locally advanced prostate cancer patients scheduled for radical…
- Conditions
- Prostate Cancer, Prostate, Prostate Cancer Patients
- Trial name
- NCT07730151
- Testing
- Darolutamide, docetaxel, ADT
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
Locally Advanced Rectal Cancer
Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
Phase II clinical trial, open-label, randomized, two arms, multicentre (possibly multinational). Academic, investigator initiated.
- Trial name
- AXEBEAM (NCT00828672)
- Testing
- Oxaliplatin, Bevacizumab, Capecitabine
- Where
- 9 sites in Belgium
- Volunteers
- 84 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer, Neoadjuvant Therapy
Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer
Today, the majority of clinically node positive (cN+) breast cancer patients is treated with neoadjuvant systemic therapy (NST). Axillary staging and treatment after NST in cN+ patients are areas of controversy.
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Lymph Node Metastases
- Trial name
- MINIMAX (NCT04486495)
- Where
- 35 sites in Netherlands
- Volunteers
- 549 people
- Sponsor
- Maastricht University Medical Center
Bladder Cancer
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery.
- Trial name
- COXEN (NCT02177695)
- Testing
- Gemcitabine, Cisplatin, Methotrexate
- Where
- 566 sites in United States
- Volunteers
- 237 people
- Sponsor
- SWOG Cancer Research Network
Pancreatic Adenocarcinoma Resectable, Non Metastatic
Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.
This is an open master platform trial, which includes multi neo-adjuvant treatment trials, multi-center, national. This platform trial evaluates the major pathological response rate (mPR) after surgery.
- Conditions
- Pancreatic Adenocarcinoma Resectable, Non Metastatic, ECOG Performance Status Score of 0 or 1
- Trial name
- POWER (NCT07808567)
- Testing
- GnP, FOLFIRINOX
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Pancreatic Adenocarcinoma
Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer
The purpose of this study is to assess the feasibility and efficacy outcomes of neoadjuvant modified FOLFIRINOX and postoperative gemcitabine in patients with borderline resectable pancreatic cancer.
- Trial name
- NCT02749136
- Testing
- Preoperative modified FOLFIRINOX and postoperative gemcitabine
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Asan Medical Center
Renal Transplantation
A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation
The hypothesis of this study is that lymphocyte depletion by Campath-1H and rituximab will obviate the need for long-term calcineurin inhibitors in renal transplantation.
- Trial name
- NCT00214266
- Testing
- Campath 1H®, Rituximab, mycophenolate mofetil
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Wisconsin, Madison
Colon Cancer
Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer
Neoadjuvant chemotherapy has been validated by several clinical studies to achieve preoperative downstaging and improve survival outcomes in patients with locally advanced colon cancer .
- Trial name
- NCT06790212
- Testing
- Ivonescimab, Oxaliplatin, Capecitabine
- Volunteers
- 168 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer
A Randomized Trial of Neoadjuvant Leuprorelin, Darolutamide or Both Prior to Radical Prostatectomy for Intermediate or High-risk Prostate Cancer.
- Trial name
- COAction (NCT06627530)
- Testing
- Darolutamide Oral Tablet, leuprorelin
- Where
- 6 sites in Brazil
- Volunteers
- 144 people
- Sponsor
- Brazilian Clinical Research Institute